Skip to main content

Phio Pharmaceuticals Corp.

corporate_fare Company Profile

Phio Pharmaceuticals Corp.

PHIO·NASDAQ·Life Sciences·CIK 0001533040

Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company that uses its proprietary INTASYL® small interfering RNA (siRNA) gene silencing technology to enhance the effectiveness of immune cells in killing tumor cells. The company is developing therapeutics that utilize INTASYL to precisely target specific proteins that weaken the body's ability to fight cancer, without requiring specialized formulations or drug delivery systems. Phio Pharmaceuticals Corp. is focused on discovering and developing innovative cancer treatments. The company operates as a single operating segment and a single reportable segment. INTASYL technology is based on RNA interference (RNAi), a biological process that inhibits gene expression or protein production. Diseases can result from incorrect protein production, excessive amounts of a specific protein, or correct protein production at the wrong location or time. RNAi offers a novel approach to drug development because RNAi compounds can be designed to silence thousands of human genes, many of which are considered "undruggable" by traditional therapeutics. The company's development efforts are based on its patented INTASYL siRNA technology, which develops specific patented compounds. INTASYL compounds consist of a unique sequence of chemically modified nucleotides (modified siRNAs) designed to target a broad range of cell types and tissues. These compounds are designed to effectively silence genes that tumors use to evade the immune system. Unlike other siRNA technologies that require cell-targeting chemical conjugates, which limit delivery to specific cell types, INTASYL aims to overcome the primary challenge of drug delivery in RNAi-based therapeutics.

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for PHIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for PHIO spans 8-K, 10-Q, 424B5, 10-K.

Recent high-impact activity:

  • Phio Receives Nasdaq Bid-Price Deficiency Notice, Has 180 Days to Regain $1.00 Compliance
  • Phio 10-Q: Going-Concern Warning, $10.6M Cash, Nasdaq Bid-Price Deficiency
  • Phio Pharmaceuticals Begins Commercial-Scale Production of Lead Drug PH-762
  • Phio Pharmaceuticals Reports Widened Q1 Loss Amid Increased R&D for PH-762, Maintains 12-Month Cash Runway
  • Phio Pharmaceuticals Completes PH-762 Phase 1b Trial with Favorable Data, Targets Q2 FDA Submission

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$8.7M
Op. Cash Flow
-$7.98M
Free Cash Flow
-$7.99M
Operating Income
-$9.22M
Cash & Equivalents
$21.03M
Debt / Equity
0.00×
Shares Outstanding
11.62M sh
Source: 10-K · filed 2026-03-05 · accession 0001437749-26-007078

Short Interest & Short Volume

1.49 days to cover

FINRA reported short interest of 86,344 shares in PHIO as of the October 30, 2026 settlement, a 36.7% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On November 20, 2026, 15.2% of PHIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)86,344 shares as of October 30, 2026
Change vs prior period▼ 36.7%
Days to cover1.49 at avg daily volume of 57,867
Daily short volume (FINRA facilities)15.2% of 111,637 shares on November 20, 2026
5-day average short volume35.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$0.715
52-week range · as of 2026-11-20 $0.6395 – $1.88
Market cap
$7.84M
Volume
145.4K (2.0× avg)
3-mo avg 71.8K
Live data · 2026-11-21 07:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PHIO - Latest Insights

PHIO
Nov 20, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.656
Real-time Price: $0.715 info
Change: +$0.059 (+9%) info
Market Cap: $7.84M info
PHIO
Nov 05, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.800
Real-time Price: $0.715 info
Change: -$0.085 (-11%) info
Market Cap: $7.84M info
PHIO
Jun 24, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.715 info
Change: -$0.355 (-33%) info
Market Cap: $7.84M info
PHIO
May 07, 2026, 4:23 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $0.715 info
Change: -$0.425 (-37%) info
Market Cap: $7.84M info
PHIO
May 07, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $0.715 info
Change: -$0.4158 (-37%) info
Market Cap: $7.84M info
PHIO
Apr 08, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $0.715 info
Change: -$0.515 (-42%) info
Market Cap: $7.84M info
PHIO
Apr 08, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.715 info
Change: -$0.525 (-42%) info
Market Cap: $7.84M info
PHIO
Apr 08, 2026, 4:13 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.715 info
Change: -$0.525 (-42%) info
Market Cap: $7.84M info
PHIO
Mar 30, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $0.715 info
Change: -$0.560 (-44%) info
Market Cap: $7.84M info
PHIO
Mar 23, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $1.22
Real-time Price: $0.715 info
Change: -$0.505 (-41%) info
Market Cap: $7.84M info
PHIO
Mar 05, 2026, 4:17 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.19
Real-time Price: $0.715 info
Change: -$0.475 (-40%) info
Market Cap: $7.84M info
PHIO
Mar 05, 2026, 4:05 PM EST
Source: TMX Newsfile
Importance Score:
9
Price at Filing: $1.17
Real-time Price: $0.715 info
Change: -$0.4572 (-39%) info
Market Cap: $7.84M info
PHIO
Feb 10, 2026, 7:33 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $0.715 info
Change: -$0.325 (-31%) info
Market Cap: $7.84M info
PHIO
Jan 20, 2026, 9:33 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $0.715 info
Change: -$0.345 (-33%) info
Market Cap: $7.84M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets